AbbVie (ABBV) Inventory Average (2013 - 2026)
AbbVie (ABBV) reported Inventory Average of $5.0 billion for Q1 2026, up 14.85% year-over-year from $4.4 billion in Q1 2025, and up 1.12% on a QoQ basis from $4.9 billion in Q4 2025.
AbbVie (ABBV) has 14 years of Inventory Average data on file, last reported at $5.0 billion in Q1 2026.
- Quarterly Inventory Average rose 14.85% year-over-year to $5.0 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.0 billion (up 14.85% YoY) and the FY2025 annual result came in at $4.6 billion, up 10.29% from the prior year.
- Inventory Average climbed to $5.0 billion in Q1 2026 per ABBV's latest filing, from $4.9 billion in the prior quarter.
- Across five years, Inventory Average topped out at $5.0 billion in Q1 2026 and bottomed at $3.3 billion in Q3 2022.
- The 5-year median for Inventory Average is $4.2 billion (2024), against an average of $4.1 billion.
- The widest annual swing landed in 2022, when Inventory Average gained 0.44%; it then grew 22.35% in 2023.
- Tracing ABBV's Inventory Average over 5 years: stood at $3.4 billion in 2022, then grew by 19.69% to $4.0 billion in 2023, then grew by 6.82% to $4.3 billion in 2024, then rose by 14.58% to $4.9 billion in 2025, then climbed by 1.12% to $5.0 billion in 2026.
- Per Business Quant, the three latest ABBV Inventory Average figures stand at $5.0 billion (Q1 2026), $4.9 billion (Q4 2025), and $4.9 billion (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inventory Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Novartis Ag | 107,124,802.25 Bn | 107,124,802.25 Bn | - | 2.74 Bn |
| 2 | Eli Lilly | 969.00 Bn | 963.72 Bn | 16.22 Bn | 14.14 Bn |
| 3 | Johnson & Johnson | 539.46 Bn | 517.41 Bn | 15.96 Bn | 14.39 Bn |
| 4 | AbbVie | 376.92 Bn | 367.57 Bn | 10.78 Bn | 5.00 Bn |
| 5 | Merck | 285.00 Bn | 279.35 Bn | 12.09 Bn | 6.57 Bn |
| 6 | Amgen | 177.58 Bn | 165.55 Bn | 5.87 Bn | 6.21 Bn |
| 7 | Gilead Sciences | 163.22 Bn | 155.50 Bn | 5.52 Bn | 1.84 Bn |
| 8 | Pfizer | 145.86 Bn | 133.09 Bn | -1.21 Bn | 10.66 Bn |
| 9 | Bristol Myers Squibb | 111.90 Bn | 101.44 Bn | 8.07 Bn | 2.72 Bn |
| 10 | Gsk | 88.34 Bn | 83.66 Bn | - | 7.58 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 5.00 Bn |
| Dec 31, 2025 | 4.94 Bn |
| Sep 30, 2025 | 4.95 Bn |
| Jun 30, 2025 | 4.74 Bn |
| Mar 31, 2025 | 4.35 Bn |
| Dec 31, 2024 | 4.32 Bn |
| Sep 30, 2024 | 4.33 Bn |
| Jun 30, 2024 | 4.23 Bn |
| Mar 31, 2024 | 4.17 Bn |
| Dec 31, 2023 | 4.04 Bn |
| Sep 30, 2023 | 4.02 Bn |
| Jun 30, 2023 | 3.94 Bn |
| Mar 31, 2023 | 3.71 Bn |
| Dec 31, 2022 | 3.38 Bn |
| Sep 30, 2022 | 3.28 Bn |
| Jun 30, 2022 | 3.44 Bn |
| Mar 31, 2022 | 3.31 Bn |
| Dec 31, 2021 | 3.11 Bn |
| Sep 30, 2021 | 3.24 Bn |
| Jun 30, 2021 | 3.33 Bn |
| Mar 31, 2021 | 3.29 Bn |
| Dec 31, 2020 | 3.39 Bn |
| Sep 30, 2020 | 3.77 Bn |
| Jun 30, 2020 | 2.95 Bn |
| Mar 31, 2020 | 1.83 Bn |
| Dec 31, 2019 | 1.87 Bn |
| Sep 30, 2019 | 1.91 Bn |
| Jun 30, 2019 | 1.80 Bn |
| Mar 31, 2019 | 1.65 Bn |
| Dec 31, 2018 | 1.70 Bn |
| Sep 30, 2018 | 1.68 Bn |
| Jun 30, 2018 | 1.66 Bn |
| Mar 31, 2018 | 1.67 Bn |
| Dec 31, 2017 | 1.70 Bn |
| Sep 30, 2017 | 1.68 Bn |
| Jun 30, 2017 | 1.50 Bn |
| Mar 31, 2017 | 1.44 Bn |
| Dec 31, 2016 | 1.54 Bn |
| Sep 30, 2016 | 1.69 Bn |
| Jun 30, 2016 | 1.77 Bn |
| Mar 31, 2016 | 1.75 Bn |
| Dec 31, 2015 | 1.78 Bn |
| Sep 30, 2015 | 1.73 Bn |
| Jun 30, 2015 | 1.32 Bn |
| Mar 31, 2015 | 1.07 Bn |
| Dec 31, 2014 | 1.07 Bn |
| Sep 30, 2014 | 1.03 Bn |
| Jun 30, 2014 | 1.08 Bn |
| Mar 31, 2014 | 1.13 Bn |
| Dec 31, 2013 | 1.16 Bn |
| Sep 30, 2013 | 1.13 Bn |
| Jun 30, 2013 | 1.06 Bn |
| Mar 31, 2013 | 1.06 Bn |